CFTX-1554 is under clinical development by Eli Lilly and Co and currently in Phase I for Peripheral Neuropathic Pain.

ANP-390 is under clinical development by AlphaNavi Pharma and currently in Phase I for Peripheral Neuropathic Pain.

A single-center retrospective study in China found a significant association between pain duration and intensity in patients ...

Cellular research indicates that neuropilin-1 plays a crucial role in pain signaling, presenting a potential pathway for ...

New Delhi: Rahi Sarnobat recalls that autumn day of 2022 with clarity. Indian shooters, following a medalless Tokyo Olympics ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) said it submitted an Investigational New Drug (IND) application to the FDA to start ...

A new study has found a potential breakthrough in the treatment of chronic pain and doesn't rely on addictive opiate ...